Policy & Regulation
Deciphera Pharmaceuticals Updated Data from Clinical Study of DCC-2618 Shows Durable Disease Control Rates in Heavily Pretreated GIST Patients
12 September 2017 - - US-based drug resistance-focused Deciphera Pharmaceuticals presented updated data from its ongoing Phase 1 clinical trial of DCC-2618, the company's pan-KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) at the European Society of Medical Oncology 2017 Congress, the company said.
The data showed that in heavily pretreated patients with GIST, treatment with DCC-2618 at ≥100 mg daily resulted in disease control rates of 76% at 12 weeks and 57% at 24 weeks.
Treatment with DCC-2618 resulted in reductions in cfDNA KIT mutant allele frequencies compared to baseline values, suggesting pan-KIT activity across the spectrum of exons 9, 11, 13, 14, 17 and 18 mutations.
DCC-2618 was generally well-tolerated at all dose levels studied, and a dose of 150 mg once per day was selected for the expansion cohorts and planned Phase 3 pivotal trials.
DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis.
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
Its small molecule drug candidates are directed against kinases, known to be directly involved in the growth and spread of many cancers. The company designs compounds that maintain kinases in a "switched off" or inactivated conformation.
These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages.